Life Science Investing Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Life Science Investing Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology Annual Meeting
Life Science Investing Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
Life Science Investing Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
Forte Minerals Closes a Second C$5.7 Million Strategic Investment and Additional Participation from Existing Strategic Investor
LaFleur Minerals Provides Update on Confirmation Drilling for PEA at Swanson Gold Deposit and Beacon Gold Mill, Val-d'Or, Québec
Cartier Cuts 111.5 g/t Au over 2.0 m at Contact ; Confirms Multiple High-Grade Gold Zones; Extends Drilling at Surface
